Skip to content

Policy Priorities

NCBIO advocates for the advancement of the life sciences industry in North Carolina so that it might meet its goal of serving the needs of its patients and customer. We promote the growth and development of the life sciences industry in the state and to ensure that its potential is maximized.

Updated February 2024

Areas of advocacy

To carry out our mission, we work closely with local, state and federal agencies to ensure the best possible outcomes for the industry, its stakeholders, citizens and patients. Our advocacy efforts include identifying issues that affect the life sciences industry, advocating for funding and policy change and working with stakeholders to ensure the industry is well-represented in the discussions that affect it.

NCBIO is committed to making sure North Carolina is a leader in the life sciences industry and that our stakeholders have a strong voice in the decision-making process. This page reflects the policy areas in which we are currently engaged.

State advocacy

Life Sciences Caucus

NCBIO collaborates with the North Carolina Life Sciences Caucus, a bipartisan legislative caucus in the North Carolina General Assembly dedicated to promoting the life sciences industry in North Carolina. The caucus works to identify and address the challenges facing the life sciences industry in the state and to create an environment that is conducive to the growth of the industry. The caucus also works to increase public awareness of the economic and social benefits that the life sciences industry brings to the state. The caucus is committed to creating an environment that will foster collaboration and innovation among the state's life sciences industry stakeholders, including universities, research institutions, industry partners and state and local governments.

The cochairs of the N.C. Life Sciences Caucus are Sen. Paul Newton, Sen. Mike Woodard, Rep. Donna White and Rep. Robert Reives.

Federal advocacy


Inflation Reduction Act of 2022

The Inflation Reduction Act (the continuing resolution passed by Congress at the end of 2021 to fund the federal government). One of its many provisions gives Medicare the power to dictate, not negotiate, the prices companies can charge for drugs and requires drug manufacturers to accept prices that other countries pay. The act also arbitrarily gives more favorable terms to biologics at the expense of small-molecule drugs.

Intellectual property and patents

Environmental issues